Idera Pharmaceuticals, Inc.
(NASDAQ : IDRA)

( )
IDRA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.32%90.401.3%$812.42m
AMGNAmgen Inc.
-0.03%186.921.2%$635.34m
GILDGilead Sciences, Inc.
0.33%66.980.9%$508.19m
BIIBBiogen Inc.
0.65%335.161.3%$445.14m
ILMNIllumina, Inc.
-0.01%302.243.5%$320.02m
REGNRegeneron Pharmaceuticals, Inc.
0.45%422.512.6%$304.29m
VRTXVertex Pharmaceuticals Incorporated
0.52%187.841.9%$269.00m
ALXNAlexion Pharmaceuticals, Inc.
0.71%129.842.0%$236.61m
SRPTSarepta Therapeutics, Inc.
0.22%140.5715.4%$155.25m
AAgilent Technologies, Inc.
1.28%78.511.6%$145.08m
EXASExact Sciences Corporation
-2.27%83.6325.3%$129.45m
INCYIncyte Corporation
-0.40%83.742.5%$115.31m
ARRYArray BioPharma Inc.
0.30%23.178.2%$109.81m
EXELExelixis, Inc.
-0.52%21.246.4%$84.04m
NBIXNeurocrine Biosciences, Inc.
-1.89%79.365.1%$80.57m

Company Profile

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. The firm uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.